Chad Gassert is VP at ANI PHARMACEUTICALS INC (ANIP). They have made 3 open-market trades across 1 company since 2022, most recently 2026-02-28.
CIK 0001871002
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $275K since 2022, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ANIP | 74,916 | $5.4M |
Shares reported on the most recent Form 4, priced at the 2026-03-02 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ANIP | SELL | 2025-11-12 | 2025-11-14 | $89.07 | $2.6M | +0.2% | -3.2% | -8.9% |
| ANIP | SELL | 2025-08-15 | 2025-08-18 | $86.97 | $1.7M | +3.5% | +6.6% | -8.3% |
| ANIP | SELL · 10b5-1 | 2024-07-01 | 2024-07-02 | $63.44 | $1.3M | +1.3% | +2.4% | -4.4% |
| ANIP | SELL · 10b5-1 | 2024-06-03 | 2024-06-04 | $64.41 | $1.3M | -3.5% | -5.3% | -2.9% |
| ANIP | SELL · 10b5-1 | 2024-05-01 | 2024-05-03 | $66.62 | $1.3M | -3.8% | -5.9% | -5.3% |
| ANIP | SELL · 10b5-1 | 2024-04-01 | 2024-04-02 | $67.25 | $1.3M | +0.4% | +0.8% | -4.7% |
| ANIP | SELL · 10b5-1 | 2024-03-11 | 2024-03-13 | $65.81 | $1.3M | +5.6% | +1.5% | -1.5% |
| ANIP | SELL · 10b5-1 | 2023-10-02 | 2023-10-03 | $56.48 | $1.1M | +2.2% | +10.9% | +1.4% |
| ANIP | SELL · 10b5-1 | 2023-09-01 | 2023-09-05 | $64.70 | $1.3M | -1.0% | -6.9% | -20.5% |
| ANIP | SELL · 10b5-1 | 2023-08-01 | 2023-08-03 | $51.06 | $1.0M | +18.0% | +19.8% | +17.6% |
| ANIP | SELL · 10b5-1 | 2023-07-03 | 2023-07-06 | $53.43 | $1.1M | -2.8% | +0.7% | +7.6% |
| ANIP | SELL · 10b5-1 | 2023-06-22 | 2023-06-23 | $51.32 | $1.0M | +4.0% | +2.7% | +15.4% |
| ANIP | BUY | 2022-03-18 | 2022-03-22 | $27.51 | $275K | +0.9% | +17.7% | -11.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.